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BACKGROUND: Platinum-based therapy (PBT) is the standard therapy for recurrent and/or metastatic head and neck cancer (HNC),
but the incidence of recurrence remains high. This study evaluates the efficacy and tolerability of capecitabine as palliative
monotherapy for recurrent HNC previously treated with PBT.
METHODS: Patients aged 18–75 years, with Eastern Cooperative Oncology Group performance status 0–2, squamous HNC with
locoregional and/or metastatic recurrence previously treated with PBT and adequate organ functions, were included. Capecitabine
(1.250mgm
 2 BID) was administered on days 1–14 every 21 days for at least two cycles.
RESULTS: A total of 40 male patients with a median age of 58 years were analysed. All patients received a median number of four cycles
of capecitabine (range: 1–9) and the median relative dose intensity was 91%. Seven patients were not evaluable for response. Overall
response rate was 24.2%. Median time to progression and overall survival were 4.8 and 7.3 months, respectively. Haematological
adverse events (AEs) grade 3/4 were reported in six patients. Most common grade 3/4 non-haematological AEs were asthenia
(12.5%), palmar-plantar eritrodisestesia (10%), mucositis (10%), dysphagia (10%) and diarrhoea (7.5%).
CONCLUSIONS: Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC
patients who have previously received PBT schedules.
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Treatment of recurrent or metastatic head and neck cancer (HNC)
is a frequent problem in daily clinical practice. Between 20 and
40% of patients with stage I or II and 470% of patients with stage
III or IV at initial diagnosis, which are treated with curative
intention, will recur (Vokes et al, 1993). Overall, locoregional
recurrence is highly common and the major cause of death in
40–60% of these patients, whereas o20% die because of distant
metastasis.
In common practice, chemotherapy (CT) is considered as the
first-line treatment in the majority of patients with recurrent
and/or metastatic HNC, with platinum-based therapy (PBT) being
the main alternative to treat symptoms (Hong and Bromer, 1983).
Recently, the introduction of epidermal growth factor receptor
(EGFR) inhibitors, such as cetuximab, together with PBT,
has improved response and survival rates in these patients
(Vermorken et al, 2008). The progressive introduction of multi-
modal treatments in which CT is used as part of an initial
treatment, either as neoadjuvant or concomitantly with radio-
therapy, results in an increasing number of patients presenting
recurrence or distant progression, who have already been treated
with platinum derivates previously (Pignon et al, 2000). In
addition, the majority of patients in this situation report disease
progression in previously radiated areas in which the possibility
of response notably diminishes. The clinical condition for these
patients is not always the optimal to receive excessively aggressive
treatments; therefore in the palliative context, the use of effective
and well-tolerated treatments is required.
Capecitabine (Xeloda; Hoffmann-La Roche Inc., Nutley, NJ,
USA) is an oral fluoropyrimidine prodrug, which is absorbed
in the gastrointestinal tract leading to 5-fluorouracil (5FU)
plasma levels, which are superior to those achieved through 5FU
intravenous infusion but with an improved safety profile because
of its selective tumour activation. Moreover, oral administration
offers the obvious advantage of convenience for patients.
Capecitabine use has been extensively studied and has been
approved in colorectal and breast cancer.
The purpose of this phase II study was to assess the efficacy
and safety of capecitabine when used as palliative mono-
therapy for recurrent and/or metastatic HNC previously treated
with PBT.
Received 5 March 2010; revised 21 April 2010; accepted 21 April 2010;
published online 18 May 2010
*Correspondence: Dr J Martinez-Trufero; E-mail: jmtrufero@seom.org
British Journal of Cancer (2010) 102, 1687–1691
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sPATIENTS AND METHODS
Eligibility
Patients with recurrent or metastatic squamous HNC who were
considered ineligible for curative surgery or chemoradiotherapy
were enrolled at selected centres belonging to the Spanish HNC
treatment Group (TTCC). Main eligibility criteria were measurable
disease as defined by Response Evaluation Criteria in Solid
Tumours (RECIST) (Therasse et al, 2000); treatment at least once
with PBT as initial treatment or as first-line treatment for
recurrent/metastatic disease. No more than one previous systemic
therapy and no CT or radiotherapy within 4 weeks of study entry
was allowed. Other eligibility criteria included the following: age
18–75 years; a negative result in pregnancy test; life expectancy of
X3 months; an Eastern Cooperative Oncology Group (ECOG)
performance status of p2; and adequate organ and marrow
function defined as a leukocyte count X3000 per ml, an absolute
neutrophil count X1500 per ml, a platelet count X100000 per ml, a
total bilirubin within normal institutional limits, plasma AST and
ALT levels p2.5 times the institutional upper limit of normal and a
creatinine level p1.5mg per 100ml; no uncontrolled serious
concomitant disease; no cavum lymphoepithelioma; and no CNS
metastasis.
The study was conducted after approval by an Independent
Ethics Committee of each site and in accordance with the
Declaration of Helsinki, Good Clinical Practices, and local ethical
and legal requirements. Signed informed consent was obtained
from all patients before study entry.
Treatment plan and dose modifications
Oral capecitabine was administered at an initial dose of
1.250mgm
 2 BID for 1–14 days, followed by a rest period of
1 week, every 21 days. Administration of capecitabine dissolved in
water or through a feeding tube was allowed for patients unable to
swallow tablets. Treatment was administered for at least three
cycles and was continued until disease progression, intercurrent
illness preventing further administration, unacceptable toxicity or
patient decision. Patients were assessed for toxicity before each
cycle using the NCI-CTCAE (National Cancer Institute common
toxicity criteria) version 2.0. Patients experiencing unacceptable
grade 2 adverse events (AEs) had therapy temporarily withheld
until resolution to grade 1 or less. If, on restarting therapy, AE
continued, the dose was decreased to 75% of the dose. Any grade
3 or 4 AE required temporary discontinuation of therapy until
resolution to grade 1 or less and restarted at 50% of the dose.
Treatment was definitively interrupted in patients whose AE did
not resolve after 2 weeks of discontinuation or who required a
second dose reduction. Once a patient’s dose was reduced, it was
not subsequently increased.
Response assessments
Patients were re-evaluated clinically, at every cycle, and radio-
graphically every three cycles. The same tumour assessment
technique was used throughout the study. Response guidelines as
defined by RECIST v1.0 criteria were used (Therasse et al, 2000).
Tumour response was evaluated after three cycles of treatment as
either a complete response (CR), partial response (PR), progressive
disease (PD) or stable disease (SD). Disease control was defined as
the sum of patients achieving a CR, PR or SD. Confirmation of
all responses was required after a minimum of 4 weeks. After
completion of study treatment, patients with SD or objective
response were followed up every 3 months until PD and/or death.
Patients were evaluated for AEs during therapy and until 28 days
after the last study drug dose.
Statistical analysis
The study used a two-stage design requiring the enrolment of 17
patients in the first stage. The study would be stopped if less than
two responses were observed at the end of the first stage. If more
than two responses were observed, an additional number of
patients were to be enrolled in the second stage to achieve the
minimum foreseen 35 evaluable patients. This design provided an
a level of 5% and a b level of 10%. The primary end point was
response rate. Secondary end points included time to progression
(TTP), overall survival (OS) and toxicity. All patients who met the
eligibility criteria and received at least three cycles of treatment
were evaluable for response and were included in the efficacy
analysis. All enrolled patients who received the study drug were
included in the toxicity analysis.
Both TTP and OS were measured from the date of enrolment
until disease progression or death, respectively, and were
summarised by Kaplan–Meier curves. Factors related to response
or lack of early progression were analysed using Fisher’s exact test,
and factors related to survival were analysed using the log-rank
test and the Cox proportional hazards model. All statistical
analyses were conducted at a level of significance of 95%
(a¼0.05).
RESULTS
Patients and eligibility
From October 2005 to July 2008, 40 patients with relapsed
oropharyngeal, larynx and oral cavity HNC were enrolled into
the study at five sites in Spain. Their characteristics are
summarised in Table 1. Median time from initial diagnosis until
inclusion in study was 17.7 months (range: 7.2–105.7).
As part of initial radical treatment, 25 patients (62.5%) had
received neoadjuvant PBT and 26 patients (65%) had received
radiotherapyþPBT concomitantly. In all, 19 patients (47.5%)
had undergone surgery previously. Seven patients (17.5%) had
received postoperative radiotherapy, four of them with concomitant
cisplatin. Median time from surgery until inclusion in the study was
22.1 months (range: 3.1–52.1). Median time from diagnosis of
recurrent/metastatic disease until inclusion in the study was 1.1
months (range: 0–52.1). Six patients (15%) had received PBT as part
of first-line treatment in recurrent/metastatic disease.
Median follow-up for all patients was 6.6 months (range:
0.6–35). Median follow-up for surviving patients was 11.5 months
(2.7–35). In total, 16 patients (40%) received subsequent rescue
therapy. In seven of them, second-line therapy was administered
after disease progression and mainly consisted of cetuximab-based
(n¼2), metotrexate (n¼2), paclitaxel plus carboplatin (n¼1) and
other (n¼5) chemotherapeutic regimens.
Treatment exposure
All patients received a total of 182 cycles of capecitabine with a
median of 4 cycles per patient (range: 1–9).
Seven patients were not evaluable for response as they do not
receive at least three cycles: three died (two because of unknown
reasons and one because of an infection), two patients because of
AEs and two because of a decrease in ECOG performance status.
All these patients were included in the toxicity analysis.
Capecitabine dose reduction was necessary in seven (3.8%)
cycles because of non-haematological (four cycles) or haemato-
logical (one cycle) AEs. A total of 33 (18.1%) cycles were delayed,
10 were delayed for non-haematological AEs, 2 for haematological
AEs, 1 because of the presence of both toxicities and 20 for
non-drug-related reasons. The median relative dose intensity was
equivalent to 91% of the predicted dose intensity.
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disease progression in 12 patients (30%), investigator criteria in
13 (32.5%), AEs in 8 (20%) patients and death in 7 patients
(17.5%).
Treatment responses
Two patients had PR after 3 cycles among the 17 patients entered
during the first stage; thus, from this standpoint, the drug was
declared sufficiently active to warrant further study in the second
stage. Of the total 40 patients enrolled, only 33 were evaluable (as
they received X3 cycles of treatment) with two CR and 6 PRs for
an overall response rate of 24.2% (95% confidence interval (95%
CI): 9.6–38.9%). A total of 18 patients (54.5%) had SD as their best
response. Therefore, as defined above, 79% of patients experienced
some degree of disease control. The remaining seven patients
(21.2%) had PD at initial re-evaluation. The median duration of
response was 8.4 months (range: 3.3–13.5 months).
TTP and OS
The median TTP was 4.8 months (95% CI: 3.2–6.3 months;
Figure 1). Median OS was 7.3 months (95% CI: 3.0–11.6 months;
Figure 2) for the entire cohort, with a survival probability of 42%
per year. In all, 15 of the 33 assessable patients continue to be alive.
Toxicity
All 40 patients were included in the toxicity analysis as they
received at least one cycle of treatment. A total of 37 patients
(92.5%) reported treatment-related AEs. A summary of the most
common treatment-related AEs per patient is shown in Table 2.
The most common were haematological (anaemia), dermatological
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Figure 2 Overall survival.
Table 1 Patient demographics (N¼40)
Patients
Characteristics No. %
Gender
Men 40 100
Age (years)
Mean (range) 58.4 (40.7–75.1)
Performance status (ECOG)
01 0 2 5
12 8 7 0
22 5
Disease status at enrolment
Local disease recurrence 33 82.5
Locoregional disease 7 17.5
Distant metastases 20 50
Lung 12
Other 8
Neoadjuvant therapy 25 62.5
Taxane–cisplatin–5FU triplets 18
Cisplatin–5FU 6
Cisplatin–docetaxel 1
Surgery 19 47.5
Primary tumour 7
Nodal disease 3
Primary tumour and nodal disease 8
Lung node metastases 1
Adjuvant therapy
RT alone 29 72.5
RT+CT with 26 65.0
Cisplatin 21
Taxane–cisplatin–5FU triplets 4
Cisplatin–docetaxel 1
Postoperative RT alone 7 17.5
Postoperative RT+CT with cisplatin 4
Recurrent/metastatic disease treatment
CT 6 15
Cisplatin–5FU 2
Carboplatin–paclitaxel 2
Cisplatin 1
Taxane–cisplatin–5FU triplets 1
RT 3 7.5
Surgery 11 27.5
Abbreviations: CT¼chemotherapy; ECOG¼Eastern Cooperative Group;
RT¼radiotherapy; 5-FU¼5-fluorouracil.
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Figure 1 Time to progression.
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and asthenia).
Grade 3/4 haematological treatment-related AEs were reported
in six patients. The most frequently observed grade 3/4
non-haematological AEs by patient were asthenia (12.5%),
palmar-plantar eritrodisestesia (10%), mucositis (10%), dysphagia
(10%) and diarrhoea (7.5%).
Eight (20%) patients discontinued treatment because of AEs.
The main reasons for discontinuation were grade 2/3 palmar-
plantar eritrodisestesia, grade 3 asthenia, grade 3 mucositis,
grade 3 diarrhoea and grade 3 vomiting.
Seven patients (17.5%) died during the study treatment, five
died within the first 60 days of the study because of PD
(one patient), unknown reasons (two patients), opioid intoxication
(one patient) and serious respiratory infection with pleural
effusion and cardiac failure (one patient).
DISCUSSION
To date, cisplatin, methotrexate, 5FU, paclitaxel and docetaxel
(Catimel et al, 1994; Forastiere et al, 1998) have been the most
widely used drugs for advanced or recurrent disease, with variable
response rates ranging from 15 to 40%. The use of poly-
chemotherapy mainly based in cisplatin–5FU combinations would
result in better response rates, but no improvement in OS has been
noted when compared with monotherapy, and the combination
has been associated with a substantial toxicity risk that is
unacceptable in the palliative setting (Forastiere et al, 1992). In
the last year, the introduction of EGFR inhibitors, such as
cetuximab, added to conventional CT has been shown to be an
efficacious instrument to improve the response rate, progression-
free survival (PFS) and OS (Vermorken et al, 2008).
The activity of capecitabine in HNC was first reported in
2002 after the results of the first phase I studies with capecita-
bine in combination with cisplatin or radiotherapy in HNC
(Arnedos et al, 2002; Pivot et al, 2003; Sykes et al, 2004). These
findings have been supported by a recent phase I study on the use
of capecitabine in combination with intensity-modulated radiation
therapy (Thomas et al, 2009). The maximal tolerable dose of
capecitabine monotherapy for phase II studies was established in
these phase I studies.
Several phase II studies have been reported with capecitabine
in combination with radiotherapy and/or CT in advanced or
recurrent HNC. Two phase II studies have been reported with
capecitabine (administered at doses of 825mgm
 2 (Kim et al,
2005) and 2000mgm
 2 (Hitt et al, 2004) on days 1–14) in
combination with cisplatin (doses of 75–80mgm
 2 on day 1)
every 21 days. Kim et al (2005) studied the capecitabine/cisplatin
combination in 37 patients with locally advanced stage. The results
observed (CR of 78.4%, PR of 16.2% and 2-year OS of 57.9%) were
comparable with those reported in most chemoradiotherapy
studies. Hitt et al (2004) evaluated the capecitabine/cisplatin
combination in 41 patients with recurrent and/or metastatic
squamous HNC, observing an ORR of 68% (RC 39%, RP 29%).
Only five patients (12%) had received PBT. Median PFS was 6.4
months and median OS was 12.6 months. Another phase II
(Bentzen and Hansen, 2007) assessed the use of capecitabine
(825mgm
 2 on days 1–14 every 21 days) in combination with
paclitaxel (175mgm
 2) every 21 days in 50 patients with recurrent
and/or metastatic HNC, observing a response rate of 42% (4% CR,
38% PR, 28% NC) and a median OS of 8 months with an acceptable
toxicity (only 10% of patients required modifications of the
foreseen dose).
In addition, one phase II study has assessed the efficacy of
capecitabine as single agent in 17 patients with recurrent and/or
metastatic nasopharyngeal carcinoma that was previously treated
with PBT (Chua et al, 2003). Capecitabine was given at doses of
1.250mgm
 2 BID for 1–14 days every 21 days, observing an ORR
of 23.5% (5.9% CR and 17.6% PR), with 52.9% SD, a median TTP
of 4.9 months and median survival of 7.6 months. Thereafter, the
same authors reported a retrospective series of 49 patients with
similar characteristics, with an ORR of 37% (6% RC, 31% RP),
median TTP of 5 months and median OS of 14 months (Chua et al,
2008). Recently, Ciuleanu et al (2008) have reported another phase
II study with capecitabine as rescue treatment (second, third
and fourth line) in 23 patients with relapsed nasopharyngeal
carcinoma, achieving 48% objective responses, with mild toxicity.
Our study is the first phase II study in recurrent and/or
metastatic HNC specifically assessing the efficacy of capecitabine
monotherapy as second-line treatment in patients previously
treated with platinum or derivates. The results obtained in the
response rates (24.2%), median TTP (4.8 months) and median OS
(7.3 months) are quite similar to those obtained with most
cytostatics, given either alone or in combination, in this sub-
population of patients.
In addition, the regimen has been well tolerated. Most common
AEs reported were consistent with those reported in other studies
with capecitabine in monotherapy (Walko and Lindley, 2005;
Aprile et al, 2009). The most frequent AEs leading to capecitabine
dose reductions, cycle delays and treatment discontinuations were
non-haematological AEs, namely, palmar-plantar eritrodisestesia,
asthenia and mucositis. Particularly, 20% of patients discontinued
treatment because of AEs. It should be noted that our patients
represent a particularly fragile subgroup, as most patients had
been previously treated with chemoradiotherapy. Generally, these
unfit patients are less capable of achieving a good compliance, and
are more vulnerable to toxic effects. Probably, this fact explains
the high proportion of early withdrawals before completing the
minimum established treatment observed in our study; however, it
also gives added value to our results when considering capecita-
bine treatment in these patients. As mentioned before, the study
drug was withdrawn early in most cases because of tumour
complications, which are characteristic of these patients, but few
Table 2 Most common (45%) AEs per patient according to NCI-CTC
grade (n¼40)
No. patients (%)
Overall (n¼40)
NCI-CTCAE toxicity Grade1/Grade2 Grade 3 Grade 4
Haematological events
Anaemia 24 (60) 2 (5.0) —
Leucopoenia 6 (15) 1 (2.5) —
Neutropaenia 4 (10) 1 (2.5) —
Low platelet count 3 (7.5) — 1 (2.5)
Non-haematological events
Palmar-plantar eritrodisestesia 11 (27.5) 3 (7.5) 1 (2.5)
Mucositis 10 (25) 4 (10.0) —
Asthenia 8 (20) 5 (12.5) —
Dysphagia 4 (10.0) 3 (7.5) 1 (2.5)
Diarrhoea 3 (7.5) 3 (7.5) —
Anorexia 5 (12.5) 1 (2.5) —
Vomiting 4 (10.0) 1 (2.5) —
Weight loss 4 (10.0) 1 (2.5) —
Bilirubin 5 (12.5) — —
Skin rash/desquamation 4 (10) — —
AST 4 (10) — —
Infection without neutropaenia 1 (2.5) 2 (5.0) —
Nausea 3 (7.5) — —
Abbreviations: AE¼adverse event; AST¼aspartate transaminase; NCI-
CTCAE¼National Cancer Institute common toxicity criteria.
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the median relative dose intensity reported was quite high (91%),
despite the discontinuation rate observed.
This regimen is also easy to be administered. Oral administra-
tion offers an alternative to the more inconvenient i.v. adminis-
tration of 5FU. In view of all these characteristics, this treatment
may be considered as a suitable therapeutic alternative in a
palliative setting. The combination of cytotoxic drugs does not
seem to provide more benefits than monotherapy in this
sub-population of patients.
Our study was mainly conceived to explore whether capecita-
bine possesses enough activity when given as monotherapy in
HNC patients to be considered for further studies. Therefore, the
impact of capecitabine monotherapy on patient’s quality of life
(QoL) was not assessed. For the same reason, this study did not
include translational research assessments. Nevertheless, these
facts do not underestimate the clinical relevance of our study.
Future studies should take into consideration QoL assessment and
the incorporation of a translational research.
The beneficial effects of novel EGFR-targeted drugs such as
cetuximab, which have been demonstrated to improve the
effectiveness of CT when added to treatment (Vermorken et al,
2008), were not available when this study was designed. Thus, with
the limits of a phase II study, data from this study should
encourage investigators to use capecitabine in combination with
new EGFR inhibitors when designing new studies in HNC patients.
In view of the effectiveness demonstrated by capecitabine, this
drug should be considered for future combination studies in HNC.
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